Sofosbuvir for the Treatment of Hepatitis C

With the FDA approval of sofosbuvir, clinicians and purchasers will need to decide whether to include sofosbuvir in their treatment protocols for HCV infection. This report evaluates the evidence about the effectiveness and harms of sofosbuvir treatment for HCV, evaluates the AASLD guideline, and provides a compilation of the evidence to guide decisions on who and when to treat. With the approval of new HCV treatments and more drug approval applications currently at the FDA, it is clear that this is a rapidly evolving clinical and policy topic. Center for Evidence-based Policy staff will continue to place updated material on the Medicaid Evidence-based Decisions (MED) Project Clearinghouse website and will consider this report for updating as new evidence emerges.

View Report